Compare SUUN & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUUN | IMA |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | Canada | United States |
| Employees | N/A | 15 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2M | 65.3M |
| IPO Year | 2024 | N/A |
| Metric | SUUN | IMA |
|---|---|---|
| Price | $0.70 | $5.96 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $5.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 969.5K | 29.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $112.68 | N/A |
| Revenue Next Year | $1.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $5.70 |
| 52 Week High | $4.75 | $17.50 |
| Indicator | SUUN | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 33.52 | 36.74 |
| Support Level | N/A | N/A |
| Resistance Level | $0.90 | $7.17 |
| Average True Range (ATR) | 0.07 | 0.33 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 23.32 | 7.89 |
PowerBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.